Skip to content
value.today
PAVmed Inc. logo

PAVmed Inc.

🇺🇸 New York, New York, USAHealth CareFounded 2014

PAVmed Inc. is listed today as PAVmed Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 7 other private sales on record. Open the number of investors for the round's details.

Funding rounds of PAVmed Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2026$30 MPrivate placement after listing$10 to $50 million

PAVmed Inc.: Private sale, Feb 2026

Investors in this round

14 investors had bought by the notice of Feb 17, 2026: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $60 M offered; $30 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis M. McGrath · Executive Officer
  • Lishan Aklog · Executive Officer, Director
  • Michael A. Gordon · Executive Officer
  • Shaun M. O'Neil · Executive Officer
  • Debra J. White · Director
  • Michael J. Glennon · Director
  • Ronald M. Sparks · Director
  • Sundeep J. Agrawal · Director
  • Timothy E. Baxter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The company sold 30,000 shares of Series D Convertible Preferred Stock at $1,000 per share, with the investors receiving warrants to purchase an additional 30,000 shares of Series D Convertible Preferred Stock at $1,000 per share.”

Signed by Dennis M. McGrath, President and Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 17, 2026. Read the notice at the SEC.

equity, optionsSEC
Jan 2025$3 MPrivate placement after listing$2 to $10 million

PAVmed Inc.: Private sale, Jan 2025

Investors in this round

1 investor had bought by the notice of Feb 7, 2025: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis M. McGrath · Executive Officer
  • Lishan Aklog · Executive Officer, Director
  • Michael A. Gordon · Executive Officer
  • Shaun M. O'Neil · Executive Officer
  • Debra J. White · Director
  • Michael J. Glennon · Director
  • Ronald M. Sparks · Director
  • Sundeep J. Agrawal · Director
  • Timothy E. Baxter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Dennis M. McGrath, President and Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 7, 2025. Read the notice at the SEC.

equitySEC
Aug 2020$8 MPrivate placement after listing$2 to $10 million

PAVmed Inc.: Private sale, Aug 2020

Investors in this round

1 investor had bought by the notice of Aug 11, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis M. McGrath · Executive Officer
  • Lishan Aklog · Executive Officer, Director
  • Richard M. Yazbeck · Executive Officer
  • Shaun M. O'Neil · Executive Officer
  • David S. Battleman, M.D. · Director
  • David Scott Weild, IV · Director
  • James L Cox · Director
  • Michael Glennon · Director
  • Ronald M. Sparks · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Dennis McGrath, President & CFO. Source: SEC Form D, newest notice filed Aug 11, 2020. Read the notice at the SEC.

debt, optionsSEC
Apr 2020$4 MPrivate placement after listing$2 to $10 million

PAVmed Inc.: Private sale, Apr 2020

Investors in this round

1 investor had bought by the notice of May 1, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
$120,250
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis M. McGrath · Executive Officer
  • Lishan Aklog · Executive Officer, Director
  • Richard M. Yazbeck · Executive Officer
  • Shaun M. O'Neil · Executive Officer
  • David S. Battleman, M.D. · Director
  • David Scott Weild, IV · Director
  • James L Cox · Director
  • Michael Glennon · Director
  • Ronald M. Sparks · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in NY

Signed by Dennis McGrath, President & CFO. Source: SEC Form D, newest notice filed May 1, 2020. Read the notice at the SEC.

debt, optionsSEC
Nov 2019$14 MPrivate placement after listing$10 to $50 million

PAVmed Inc.: Private sale, Nov 2019

Investors in this round

2 investors had bought by the notice of Nov 7, 2019: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
$819,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis M. McGrath · Executive Officer
  • Lishan Aklog · Executive Officer, Director
  • Richard M. Yazbeck · Executive Officer
  • Shaun M. O'Neil · Executive Officer
  • David S. Battleman, M.D. · Director
  • David Scott Weild, IV · Director
  • James L. Cox · Director
  • Michael Glennon · Director
  • Ronald M. Sparks · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “For further explanation, please see the Current Reporton Form 8-K filed by the Issuer on November 4, 2019.”
  • On the amounts: “For further explanation, please see the Current Report on Form 8-K filed by the Issuer on November 4, 2019.”

Signed by Lishan Aklog, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 7, 2019. Read the notice at the SEC.

debt, optionsSEC
Dec 2018$8 MPrivate placement after listing$2 to $10 million

PAVmed Inc.: Private sale, Dec 2018

Investors in this round

1 investor had bought by the notice of Jan 9, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
$455,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian J. DeGuzman, M.D. · Executive Officer
  • Dennis M. McGrath · Executive Officer
  • Lishan Aklog, M.D. · Executive Officer, Director
  • David S. Battleman, M.D. · Director
  • David Scott Weild, IV · Director
  • James L. Cox, M.D. · Director
  • Michael Glennon · Director
  • Ronald M. Sparks · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in NY

Signed by Lishan Aklog, M.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 9, 2019. Read the notice at the SEC.

debt, optionsSEC
Jan 2017$2 MPrivate placement after listingUnder $2 million

PAVmed Inc.: Private sale, Jan 2017

Investors in this round

13 investors had bought by the notice of Feb 7, 2017: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$105,556
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lishan Aklog · Executive Officer, Director
  • Richard Fitzgerald · Executive Officer
  • David M. Weild, IV · Director
  • Ira Scott Grenspan · Director
  • James L. Cox · Director
  • Joshua R. Lamstein · Director
  • Michael Glennon · Director
  • Ronald M. Sparks · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Xzerta Trading LLC d/b/a HCFP/Capital Markets (CRD 149111) · New York, New YorkSold in CA, CT, NJ, NY

Signed by Lishan Aklog, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 7, 2017. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • PAVmed Inc. had revenue between $1 million and $5 million when it filed its newest notice of a funding round (Feb 2026).

    SEC Form D (revenue range) · Feb 2026

  • Revenue range over time, as stated in its notices: no revenue in 2019; no revenue in 2020; revenue between $1 million and $5 million in 2025; revenue between $1 million and $5 million in 2026.

    SEC Form D (revenue range) · Feb 2026

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Feb 2026

Products and services#

No products or services of PAVmed Inc. are on record.

Investors#

No investor of PAVmed Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding PAVmed Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by PAVmed Inc.
NameRoleNamed in
Dennis M. McGrathExecutive officerFeb 2026
Lishan AklogExecutive officerFeb 2026
Michael A. GordonExecutive officerFeb 2026
Shaun M. O'NeilExecutive officerFeb 2026
Richard M. YazbeckExecutive officerAug 2020
Brian J. DeGuzman, M.D.Executive officerJan 2019
Lishan Aklog, M.D.Executive officerJan 2019
Richard FitzgeraldExecutive officerFeb 2017
Debra J. WhiteDirectorFeb 2026
Lishan AklogDirectorFeb 2026
Michael J. GlennonDirectorFeb 2026
Ronald M. SparksDirectorFeb 2026
Sundeep J. AgrawalDirectorFeb 2026
Timothy E. BaxterDirectorFeb 2026
David S. Battleman, M.D.DirectorAug 2020
David Scott Weild, IVDirectorAug 2020
James L CoxDirectorAug 2020
Michael GlennonDirectorAug 2020
James L. CoxDirectorNov 2019
James L. Cox, M.D.DirectorJan 2019
Lishan Aklog, M.D.DirectorJan 2019
David M. Weild, IVDirectorFeb 2017
Ira Scott GrenspanDirectorFeb 2017
Joshua R. LamsteinDirectorFeb 2017

Went public since 2016. Its SEC number is that of a company listed on a stock exchange.